JP2023553005A5 - - Google Patents

Info

Publication number
JP2023553005A5
JP2023553005A5 JP2023534050A JP2023534050A JP2023553005A5 JP 2023553005 A5 JP2023553005 A5 JP 2023553005A5 JP 2023534050 A JP2023534050 A JP 2023534050A JP 2023534050 A JP2023534050 A JP 2023534050A JP 2023553005 A5 JP2023553005 A5 JP 2023553005A5
Authority
JP
Japan
Prior art keywords
aav
viral vector
composition according
pmp22
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023534050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023553005A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/061177 external-priority patent/WO2022119826A1/en
Publication of JP2023553005A publication Critical patent/JP2023553005A/ja
Publication of JP2023553005A5 publication Critical patent/JP2023553005A5/ja
Pending legal-status Critical Current

Links

JP2023534050A 2020-12-01 2021-11-30 末梢ミエリンタンパク質22の発現の阻害のための生成物及び方法 Pending JP2023553005A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063120190P 2020-12-01 2020-12-01
US63/120,190 2020-12-01
PCT/US2021/061177 WO2022119826A1 (en) 2020-12-01 2021-11-30 Products and methods for inhibition of expression of peripheral myelin protein-22

Publications (2)

Publication Number Publication Date
JP2023553005A JP2023553005A (ja) 2023-12-20
JP2023553005A5 true JP2023553005A5 (cg-RX-API-DMAC7.html) 2024-11-18

Family

ID=81853504

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023534050A Pending JP2023553005A (ja) 2020-12-01 2021-11-30 末梢ミエリンタンパク質22の発現の阻害のための生成物及び方法

Country Status (9)

Country Link
US (1) US20240318172A1 (cg-RX-API-DMAC7.html)
EP (1) EP4256069A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023553005A (cg-RX-API-DMAC7.html)
KR (1) KR20230134477A (cg-RX-API-DMAC7.html)
CN (1) CN116917492A (cg-RX-API-DMAC7.html)
AU (1) AU2021390471A1 (cg-RX-API-DMAC7.html)
CA (1) CA3203748A1 (cg-RX-API-DMAC7.html)
IL (1) IL303308A (cg-RX-API-DMAC7.html)
WO (1) WO2022119826A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118251492A (zh) * 2021-11-18 2024-06-25 诺华股份有限公司 用于治疗夏科-马里-图思病的靶向pmp22的化合物
AU2024265701A1 (en) 2023-05-02 2025-12-04 Research Institute At Nationwide Children's Hospital A modular system to convert therapeutic microrna expression cassettes from polymerase iii-based to polymerase ii-based promoters
WO2025150052A1 (en) * 2024-01-12 2025-07-17 Potentia Ltd. Targeted delivery of drug conjugates to schwann cells and treatment methods in schwann cell-related diseases
WO2025242147A1 (zh) * 2024-05-21 2025-11-27 北京安龙生物医药有限公司 靶向外周髓鞘蛋白-22基因的寡核苷酸及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2847458C (en) * 2000-12-13 2019-11-12 Baylor College Of Medicine Defects in periaxin associated with myelinopathies
US20040018522A1 (en) * 2002-05-09 2004-01-29 Brigham And Women's Hospital, Inc. Identification of dysregulated genes in patients with multiple sclerosis
EP3495472B1 (en) * 2011-04-21 2023-11-15 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of myotilin
CA2842798C (en) * 2011-07-25 2021-02-23 Nationwide Children's Hospital, Inc. Recombinant virus products and methods for inhibition of expression of dux4
HK1214521A1 (zh) * 2012-11-05 2016-07-29 Genzyme Corporation 用於治療蛋白質病的組合物和方法
KR102298579B1 (ko) * 2013-05-21 2021-09-07 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 캡시드-변형된 raav3 벡터 조성물, 및 인간 간암의 유전자 요법에서의 용도
WO2015153760A2 (en) * 2014-04-01 2015-10-08 Sangamo Biosciences, Inc. Methods and compositions for prevention or treatment of a nervous system disorder
AU2016370630B2 (en) * 2015-12-14 2023-04-13 The Trustees Of The University Of Pennsylvania Adeno-associated viral vectors useful in treatment of spinal muscular atropy
AU2017229778A1 (en) * 2016-03-09 2018-08-16 Ionis Pharmaceuticals, Inc. Methods and compositions for inhibiting PMP22 expression
EP4650364A3 (en) * 2016-07-06 2026-01-21 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
KR101872105B1 (ko) * 2016-09-05 2018-06-27 사회복지법인 삼성생명공익재단 샤르코 마리 투스병 치료용 약학 조성물
JP7277052B2 (ja) * 2017-02-22 2023-05-18 クリスパー セラピューティクス アーゲー プロタンパク質転換酵素サブチリシン/ケキシン9型(pcsk9)関連障害の処置のための組成物および方法
WO2019066490A2 (ko) * 2017-09-28 2019-04-04 주식회사 툴젠 유전자 발현 조절을 위한 인위적인 게놈 조작
AU2019328270B2 (en) * 2018-08-29 2026-02-26 Research Institute At Nationwide Children's Hospital Products and methods for inhibition of expression of mutant GARS protein
EP3628735A1 (en) * 2018-09-25 2020-04-01 Centre National De La Recherche Scientifique Antisense rna targeting pmp22 for the treatment of charcot-marie-tooth 1a disease
EP3897837A4 (en) * 2018-12-21 2023-08-16 Ionis Pharmaceuticals, Inc. COMPOUNDS AND METHODS FOR REDUCING PMP22 EXPRESSION
KR20200124038A (ko) * 2019-04-23 2020-11-02 사회복지법인 삼성생명공익재단 마이크로rna-381을 유효성분으로 포함하는, pmp22 과발현에 의한 말초신경병증의 예방 또는 치료용 약학적 조성물
JP2022540446A (ja) * 2019-07-10 2022-09-15 ロックアネイビオ, インコーポレイテッド Rna標的ノックダウン及び置換の組成物及び使用方法
WO2021258011A1 (en) * 2020-06-19 2021-12-23 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating pmp22

Similar Documents

Publication Publication Date Title
JP7395550B2 (ja) 新規アデノ随伴ウイルスキャプシドタンパク質
US11939597B2 (en) Restrictive inverted terminal repeats for viral vectors
US20220331409A1 (en) Factor ix gene therapy
JP2020019772A5 (cg-RX-API-DMAC7.html)
JP2020522269A5 (cg-RX-API-DMAC7.html)
JP2025162557A5 (cg-RX-API-DMAC7.html)
JP2007507223A5 (cg-RX-API-DMAC7.html)
IL320714A (en) Gene therapy for limb-girdle muscular dystrophy type 2c
IL320791A (en) Muscle-specific delivery of microdystrophin using an adeno-associated virus vector for the treatment of muscular dystrophy
CN112424217A (zh) 肝脏靶向的腺病毒相关病毒载体
JP2017510298A5 (cg-RX-API-DMAC7.html)
JP2021534755A5 (cg-RX-API-DMAC7.html)
JP2021534794A5 (cg-RX-API-DMAC7.html)
JP2023524414A5 (cg-RX-API-DMAC7.html)
JP2022530095A5 (cg-RX-API-DMAC7.html)
JP2025539750A (ja) 前頭側頭型認知症の遺伝子治療
EP4085143B1 (en) Improved aav-abcd1 constructs and use for treatment or prevention of adrenoleukodystrophy (ald) and/or adrenomyeloneuropathy (amn)
JP2025540074A (ja) 繰り返しエレメントの適切なパッケージングのためのアデノ随伴ウイルスベクター
JP2024543211A5 (cg-RX-API-DMAC7.html)
JP2023529371A5 (cg-RX-API-DMAC7.html)
JP2022522166A5 (cg-RX-API-DMAC7.html)
AU2022282057B2 (en) Novel dual helper plasmid
JP2024514160A5 (cg-RX-API-DMAC7.html)
JP2023541444A5 (cg-RX-API-DMAC7.html)
JP2024537167A5 (cg-RX-API-DMAC7.html)